(RTTNews.com) - Puma Biotechnology Inc. ( PBYI ) announced results from the Phase III clinical trial of PB272, or neratinib, after the close Tuesday. The trial demonstrated that treatment with neratinib resulted in a 33% improvement in disease free survival versus placebo for the primary endpoint of disease free survival in the treatment of patients with breast cancer
Read more: http://www.nasdaq.com/article/puma-...-on-phase-3-data-20140723-00579#ixzz38L6KPuma Biotechnology has gapped open dramatically higher Wednesday morning and is now up 164.97 at $224.00 on strong volume. The stock has surged to a new high
went up $174
- Forums
- ASX - By Stock
- PAB
- Ann: Patrys Reports Progress on Preclinical Programmes
PAB
patrys limited
Add to My Watchlist
33.3%
!
0.1¢

Ann: Patrys Reports Progress on Preclinical Programmes, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.1¢ |
Change
-0.001(33.3%) |
Mkt cap ! $2.365M |
Open | High | Low | Value | Volume |
0.2¢ | 0.2¢ | 0.1¢ | $15.37K | 11.45M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
36 | 76854880 | 0.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.2¢ | 32246949 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
36 | 76854880 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.002 | 32246949 | 21 |
0.003 | 12789492 | 8 |
0.004 | 700000 | 1 |
0.005 | 624000 | 3 |
0.006 | 300000 | 1 |
Last trade - 16.10pm 08/07/2025 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |